1. A combination vertical inhibition approach with inhibitors of SHP2 and ERK provides improved activity in KRAS-mutant pancreatic and colorectal cancer models. (October 2022) Authors: Hindley, C.; Biondo, A.; Brothwood, J.; Dao, K.H.; Kandola, N.; Lyons, J.; Nakatsuru, Y.; Smyth, T.; Wagner, S.; Wallis, N.; Hearn, K. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Combined inhibition of SHP2 and ERK enhances anti-tumour effects in preclinical models. (October 2020) Authors: Smyth, T.; Brothwood, J.; Fazal, L.; Hearn, K.; Hindley, C.; Johnson, C.; Jones, M.; Kandola, N.; Lyons, J.; Martins, V.; Miyadera, K.; Muench, S.; Munck, J.; Nakatsuru, Y.; Ochiiwa, H.; Saini, H.; Shah, A.; Wagner, S.; Wilsher, N.; Wallis, N. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Development of a Novel IGF2BP1 Inhibitor as Metastasis-Specific Therapeutic Agent. (October 2022) Authors: Singh, A.; Singh, V.; Wallis, N.; Elimelech, O.; Oberman, F.; Ramos, A.; Yisraeli, J.; Spiegelman, V.; Sharma, A. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S104 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Large-scale implementation of pooled RNA extraction and RT-PCR for SARS-CoV-2 detection. (September 2020) Authors: Ben-Ami, R.; Klochendler, A.; Seidel, M.; Sido, T.; Gurel-Gurevich, O.; Yassour, M.; Meshorer, E.; Benedek, G.; Fogel, I.; Oiknine-Djian, E.; Gertler, A.; Rotstein, Z.; Lavi, B.; Dor, Y.; Wolf, D.G.; Salton, M.; Drier, Y.; Klochendler, A.; Eden, A.; Klar, A. Journal: Clinical microbiology and infection Issue: Volume 26:Number 9(2020) Page Start: 1248 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Low SKP2 expression is predictive of sensitivity to an MDM2 antagonist in p53 wild-type AML. (October 2022) Authors: Kucia-Tran, J.; Bevan, L.; Chessari, G.; Fazal, L.; Ferrari, N.; Lyons, J.; Saini, H.; Wallis, N.; Ward, G.; Ahn, M. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S83 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The clinical candidate, ASTX029, is a novel, dual mechanism ERK1/2 inhibitor and has potent activity in MAPK-activated cancer cell lines and in vivo tumor models. (October 2020) Authors: Munck, J.; Berdini, V.; Courtin, A.; East, C.; Heightman, T.; Hindley, C.; Kucia-Tran, J.; Lyons, J.; Martins, V.; Muench, S.; Murray, C.; Norton, D.; O'Reilly, M.; Reader, M.; Rees, D.; Rich, S.; Thompson, N.; Wilsher, N.; Woolford, A.; Wallis, N. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S53 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Therapy‐induced clearance of HCV core antigen from plasma predicts an end of treatment viral response. Issue 1 (4th July 2012) Authors: Tedder, R. S.; Tuke, P.; Wallis, N.; Wright, M.; Nicholson, L.; Grant, P. R. Journal: Journal of viral hepatitis Issue: Volume 20:Issue 1(2013) Page Start: 65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗